№ US20260000664A1발명
심사 중TREATING PATIENTS HARBORING AN ISOCITRATE DEHYDROGENASE-1 (IDH-1) MUTATION
TREATING PATIENTS HARBORING AN ISOCITRATE DEHYDROGENASE-1 (IDH-1) MUTATION
Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.
❖FORMA Therapeutics, Inc.Patrick F. Kelly; Alan Collis; Jeff Davis; Duncan Walker; Susan Ashwell; Blythe Thomson; Wei Lu§ 2/22 청구항A61K 31/4709, A61P 35/2, C12Q 1/686 +18